Richard J. Ablin
Corporate Officer/Principal at Tetragenex Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Abel | M | 79 |
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 years |
| Martin F. Schacker | M | 65 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 years |
| Aaron S. Cohen | M | 87 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 years |
| William T. Comer | M | 85 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 years |
| Bruce J. Bergman | M | 76 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 years |
| Alf E. F. Akerman | M | 58 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 years |
| Kenneth Cartwright | M | 86 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 35 years |
| Robert Peter Budetti | M | 79 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 years |
| Mitchell H. Pally | M | - |
The State University of New York
| 35 years |
| Joseph J. Hlavka | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 31 years |
| Gabriela Nicolau | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 29 years |
| Russell W. Bessette | M | - |
The State University of New York
| 35 years |
| Steven J. Scheinman | M | - |
The State University of New York
| 40 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Qiong Pan | F | 69 |
The State University of New York
| 5 years |
| Joseph B. Rizzo | M | 59 |
The State University of New York
| 7 years |
| Chris Montclare | M | - |
The State University of New York
| 5 years |
| Dov Elefant | M | 56 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 8 years |
| Kenneth J. Yanneck | M | - |
The State University of New York
| 5 years |
| Ambuj Kumar Jain | M | - |
The State University of New York
| 6 years |
| Paul G. Sedlack | M | - |
The State University of New York
| 6 years |
| Neil Martucci | M | 49 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 9 years |
| Ambuj A. J. Jain | M | - |
The State University of New York
| 6 years |
| Keith David Weigel | M | - |
The State University of New York
| 9 years |
| Robert John Murphy | M | - |
The State University of New York
| 6 years |
| Chun Ching Cheng | M | - |
The State University of New York
| 4 years |
| Denise S. Hawkins | F | 54 |
The State University of New York
| 4 years |
| William M. Steul | M | 81 |
State University of New York at Buffalo
| 2 years |
| Michael W. Williams | M | - |
The State University of New York
| 6 years |
| Cengiz Erol | M | - |
The State University of New York
| 5 years |
| Ahmed Al-Zaim | M | 58 |
The State University of New York
| 4 years |
| Jacqueline H. Berge | F | - |
The State University of New York
| 4 years |
| Terry Murphy | M | 61 |
The State University of New York
| 4 years |
| Richard Jay Perez | M | - |
The State University of New York
| 4 years |
| John Paul Tomassetti | M | - |
The State University of New York
| 4 years |
| Gay Snow | F | - |
The State University of New York
| 4 years |
| Yvan-Claude J. Pierre | M | - |
The State University of New York
| 4 years |
| Jerzy Pawlowski | M | - |
The State University of New York
| 3 years |
| Kathirgamasundaram Sooriakumar | M | 60 |
The State University of New York
| 4 years |
| Da Qing Nan | M | 65 |
The State University of New York
| 2 years |
| John Sheehan | M | - |
The State University of New York
| 4 years |
| Joseph A. Saccomano | M | - |
The State University of New York
| 4 years |
| Steven P. Schaefer | M | 63 |
The State University of New York
| 4 years |
| Zuo Yi Wang | M | 62 |
The State University of New York
| 2 years |
| Kevin Sesny | M | - |
The State University of New York
| 2 years |
| Sherri Hurwitz | F | - |
The State University of New York
| 4 years |
| Debby Gilbert | F | - |
The State University of New York
| 4 years |
| Allison A. Campbell | M | - |
The State University of New York
| 3 years |
| Gail Hunter | F | - |
The State University of New York
| 4 years |
| Beth Maguire | F | - |
The State University of New York
| 4 years |
| Bethany R. Smith | F | - |
The State University of New York
| 4 years |
| Bruce Mitchell Kallins | M | - |
The State University of New York
| 4 years |
| William J. Nason | M | - |
The State University of New York
| 4 years |
| Matthew Daly | M | - |
The State University of New York
| 4 years |
| Michael Hirschberg | M | 60 |
The State University of New York
| 4 years |
| Richard Ringel | M | - |
The State University of New York
| 4 years |
| Mike H. Meyer | M | - |
The State University of New York
| 4 years |
| Alan Kwong | M | 64 |
The State University of New York
| 4 years |
| Craig Schorling | M | - |
The State University of New York
| 4 years |
| Si Yuan Le | M | - |
The State University of New York
| 5 years |
| Sharon L. Smith | F | - |
The State University of New York
| 4 years |
| Ming Dong Zhou | M | 69 |
The State University of New York
| 5 years |
| Timothy Kuniskis | M | 57 |
The State University of New York
| 4 years |
| Todd Kevin Koffman | M | - |
The State University of New York
| 4 years |
| Juli Marley | F | - |
The State University of New York
| 4 years |
| John J. D'Angelo | M | - |
The State University of New York
| 4 years |
| Mark Alan Lozina | M | - |
The State University of New York
| 4 years |
| Michael Rindos | M | - |
The State University of New York
| 4 years |
| Jeffrey Peck | M | - |
The State University of New York
| 4 years |
| Steven Eric Kent | M | 61 |
The State University of New York
| 3 years |
| Jim McGrath | M | - |
The State University of New York
| 4 years |
| Todd Wakefield | M | - |
The State University of New York
| 14 years |
| Jeffrey Grill | M | - |
The State University of New York
| 4 years |
| Alan Pavese | M | - |
The State University of New York
| 4 years |
| Peter J. St. Denis | M | - |
The State University of New York
| 4 years |
| Bruce Howard Geller | M | 55 |
The State University of New York
| 4 years |
| Edward J. Weisberger | M | 59 |
The State University of New York
| 4 years |
| John T. Quinn | M | 60 |
The State University of New York
| 4 years |
| Daniel Patrick Mody | M | - |
The State University of New York
| 4 years |
| Craig Bell | M | 66 |
The State University of New York
| 3 years |
| Ira Edelblum | M | - |
The State University of New York
| 4 years |
| Ronald Frimmer | M | - |
The State University of New York
| 4 years |
| Aaron Kilberg | M | - |
The State University of New York
| 4 years |
| Richard Alan Friedman | M | 61 |
The State University of New York
| 4 years |
| Dan Loughran | M | - |
The State University of New York
| 4 years |
| Josh Hay | M | - |
The State University of New York
| 4 years |
| Mike Crill | M | - |
The State University of New York
| 4 years |
| Steven A. Navarro | M | - |
The State University of New York
| 4 years |
| Rocky Mountain | M | - |
The State University of New York
| 5 years |
| Christos J. P. Moschovitis | M | - |
The State University of New York
| 4 years |
| Lloyd S. Harmetz | M | - |
The State University of New York
| 4 years |
| Roy Notowitz | M | - |
The State University of New York
| 4 years |
| Joseph L. DeFrancisci | M | 64 |
The State University of New York
| 4 years |
| Stuart Novick | M | - |
The State University of New York
| 4 years |
| Jeffrey L. Hale | M | 61 |
The State University of New York
| 4 years |
| Steve Silver | M | - |
The State University of New York
| 4 years |
| Paul E. Pompeo | M | - |
The State University of New York
| 4 years |
| Mike Rundle | M | - |
The State University of New York
| 4 years |
| Albert R. Crespo | M | - |
The State University of New York
| 4 years |
| Melinda Jocelyn Newman | F | - |
The State University of New York
| 6 years |
| Hai Tao Peng | M | 65 |
The State University of New York
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard J. Ablin
- Personal Network
